JP2022525754A - 医療用ｎｇｆアンタゴニスト - Google Patents

医療用ｎｇｆアンタゴニスト Download PDF

Info

Publication number
JP2022525754A
JP2022525754A JP2021555430A JP2021555430A JP2022525754A JP 2022525754 A JP2022525754 A JP 2022525754A JP 2021555430 A JP2021555430 A JP 2021555430A JP 2021555430 A JP2021555430 A JP 2021555430A JP 2022525754 A JP2022525754 A JP 2022525754A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
igg
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525754A5 (https=
Inventor
ハンチュン チャン，
ラム グェン，
リチャード チン，
フォーン チエン，
シー ジアン リー，
チンイー チュー，
Original Assignee
キンドレッド バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キンドレッド バイオサイエンシズ インコーポレイテッド filed Critical キンドレッド バイオサイエンシズ インコーポレイテッド
Publication of JP2022525754A publication Critical patent/JP2022525754A/ja
Publication of JP2022525754A5 publication Critical patent/JP2022525754A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2021555430A 2019-03-20 2020-03-20 医療用ｎｇｆアンタゴニスト Pending JP2022525754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821438P 2019-03-20 2019-03-20
US62/821,438 2019-03-20
PCT/US2020/023846 WO2020191289A1 (en) 2019-03-20 2020-03-20 Ngf antagonists for medical use

Publications (2)

Publication Number Publication Date
JP2022525754A true JP2022525754A (ja) 2022-05-19
JP2022525754A5 JP2022525754A5 (https=) 2023-03-16

Family

ID=72521232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555430A Pending JP2022525754A (ja) 2019-03-20 2020-03-20 医療用ｎｇｆアンタゴニスト

Country Status (10)

Country Link
US (1) US20220169740A1 (https=)
EP (1) EP3941933A4 (https=)
JP (1) JP2022525754A (https=)
KR (1) KR20220066002A (https=)
CN (1) CN113840831A (https=)
AU (1) AU2020240120A1 (https=)
BR (1) BR112021018156A2 (https=)
CA (1) CA3133104A1 (https=)
MX (1) MX2021011335A (https=)
WO (1) WO2020191289A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
KR20230005875A (ko) * 2020-04-22 2023-01-10 킨드레드 바이오사이언시스, 인코포레이티드 수의학 용도를 위한 장시간-작용성 항-il31 항체
AU2022329459A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
EP4419547A1 (en) * 2021-10-21 2024-08-28 Petmedix Ltd. Proteins comprising the extracellular domain of p75ntr
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
KR20250141832A (ko) * 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511262A (ja) * 1998-04-09 2002-04-16 ザ ユニバーシティ オブ ブリストル Ｎｇｆに関する治療薬
JP2004506694A (ja) * 2000-08-18 2004-03-04 ザ　ユニバーシティ　オブ　ブリストル 癌の防止および／または治療に使用するためのｔｒｋａｉｇ２を含む薬学的組成物
US20070162990A1 (en) * 2006-01-11 2007-07-12 Yuan-Jang Tsai Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
WO2014184564A1 (en) * 2013-05-15 2014-11-20 Polytherics Limited Novel polymer conjugates
WO2015064621A1 (ja) * 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
US20160129012A1 (en) * 2014-11-07 2016-05-12 Children's Hospital Medical Center Compositions and methods for treating allergic inflammation through inhibition of ntrk1
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2007059574A1 (en) * 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2016035052A1 (en) * 2014-09-05 2016-03-10 Nvip Pty Ltd Anti-nerve growth factor antibodies for treating itching
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511262A (ja) * 1998-04-09 2002-04-16 ザ ユニバーシティ オブ ブリストル Ｎｇｆに関する治療薬
JP2004506694A (ja) * 2000-08-18 2004-03-04 ザ　ユニバーシティ　オブ　ブリストル 癌の防止および／または治療に使用するためのｔｒｋａｉｇ２を含む薬学的組成物
US20070162990A1 (en) * 2006-01-11 2007-07-12 Yuan-Jang Tsai Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
WO2014184564A1 (en) * 2013-05-15 2014-11-20 Polytherics Limited Novel polymer conjugates
WO2015064621A1 (ja) * 2013-10-29 2015-05-07 公益財団法人がん研究会 新規融合体及びその検出法
US20160129012A1 (en) * 2014-11-07 2016-05-12 Children's Hospital Medical Center Compositions and methods for treating allergic inflammation through inhibition of ntrk1
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Canine TrkA / NTRK1 Protein (Fc Tag), Catalog Number:70101-D01H", SINO BIOLOGICAL INC., JPN7024001727, 2016, ISSN: 0005519322 *
MILENA DE MELO-JORGE AND MERCIO PEREIRAPERRIN, CELL HOST & MICROBE, vol. 1, JPN6024016315, 2007, pages 251 - 261, ISSN: 0005519321 *
SCHAFERS M ET AL.: "Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tum", J NEUROSCI, vol. Vol.23(7), JPN6025003953, 2003, pages 3028 - 3038, ISSN: 0005519324 *
SCHAFERS M ET AL.: "Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation o", J NEUROSCI, vol. Vol.23(7), JPN6025003952, 2003, pages 2517 - 2521, ISSN: 0005519323 *

Also Published As

Publication number Publication date
WO2020191289A1 (en) 2020-09-24
MX2021011335A (es) 2022-01-06
BR112021018156A2 (pt) 2021-11-16
KR20220066002A (ko) 2022-05-23
US20220169740A1 (en) 2022-06-02
AU2020240120A1 (en) 2021-09-30
CA3133104A1 (en) 2020-09-24
EP3941933A1 (en) 2022-01-26
EP3941933A4 (en) 2023-07-26
CN113840831A (zh) 2021-12-24

Similar Documents

Publication Publication Date Title
JP2022525754A (ja) 医療用ｎｇｆアンタゴニスト
US20240316161A1 (en) Fibronectin based scaffold domain proteins that bind to myostatin
JP7691365B2 (ja) 動物用ＩｇＧＦｃバリアント
JP2026048634A (ja) 獣医学用ｉｇｇ ｆｃ変異体
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
JP7671275B2 (ja) 動物用の抗ｉｌ３１抗体
WO2020086886A1 (en) Il4/il13 receptor molecule for veterinary use
US11299540B2 (en) IL17A antibodies and antagonists for veterinary use
RU2829812C2 (ru) Антагонисты ngf для медицинского использования
RU2850882C2 (ru) Варианты fc igg для ветеринарного применения
RU2795591C2 (ru) Молекула рецептора il4/il13 для ветеринарного применения
HK40060829A (en) Igg fc variants for veterinary use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729